Medivir AB, a research-based pharmaceutical company, declared the successful finishing of the pre-clinical safety studies for MIV-818 to allow the start of phase I clinical trials in 2018. For the treatment of hepatocellular carcinoma (HCC) and other forms of liver cancer, MIV-818 is Medivir’s proprietary liver-targeted on nucleotide prodrug.
It is the first development project to emerge from Medivir’s in-house drug discovery efforts in oncology. With the successful completion of the pre-clinical safety studies on MIV-818, Medivir means to make the vital regulatory submissions during the first half of 2018 and to begin the first clinical trials of MIV-818 during the second 50% of 2018.
Richard Bethell, Medivir’s chief scientific officer said, “patients with HCC and other forms of liver cancer are in urgent need of new treatment options.
MIV-818 has been designed to deliver high levels of the active form of the drug to the liver after oral administration while minimizing its exposure somewhere else in the body.
This targeted approach to cancer chemotherapy can potential is an important new treatment for liver cancers, either alone or in combination with other therapeutic modalities”.
Christine Lind, CEO of Medivir said, “We are delighted that we now can enter clinical phase with MIV-818. It clearly underlines the strength of our in-house drug discovery platform and our prodrug expertise”.
Liver cancer is the second highest reason for cancer-related death around the world. Of the different forms of liver cancer, HCC is the most prevalent. It is classified an orphan disease in the West but is more typical in Asia in general, and China specifically.
MIV-818 can possibly become into the first liver-targeted, orally administered drug to address HCC and other forms of liver cancer.
The company includes a main competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to developing innovative pharmaceuticals that meet incredible unmet therapeutic needs.